Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Retained Earnings (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Retained Earnings for 11 consecutive years, with -$1.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 13.12% year-over-year to -$1.1 billion, compared with a TTM value of -$1.1 billion through Dec 2025, down 13.12%, and an annual FY2025 reading of -$1.1 billion, down 13.12% over the prior year.
  • Retained Earnings was -$1.1 billion for Q4 2025 at Spyre Therapeutics, down from $791000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $791000.0 in Q3 2025 and bottomed at -$1.1 billion in Q2 2025.
  • Average Retained Earnings over 5 years is -$446.8 million, with a median of -$386.5 million recorded in 2022.
  • The sharpest move saw Retained Earnings tumbled 20340100.0% in 2022, then skyrocketed 100.09% in 2025.
  • Year by year, Retained Earnings stood at -$20000.0 in 2021, then crashed by 140.0% to -$48000.0 in 2022, then crashed by 1592429.17% to -$764.4 million in 2023, then dropped by 27.21% to -$972.4 million in 2024, then decreased by 13.12% to -$1.1 billion in 2025.
  • Business Quant data shows Retained Earnings for SYRE at -$1.1 billion in Q4 2025, $791000.0 in Q3 2025, and -$1.1 billion in Q2 2025.